We have read with great interest the recently published article authored by Li *et al*. \[[@ref1]\]. In their cross-sectional study, the authors demonstrated that elevated fasting plasma glucose was significantly more frequent among overweight/obese patients compared to lean patients with non-alcoholic fatty liver disease (NAFLD) \[[@ref1]\].

In another, recently published cross-sectional study enrolling 1,509 patients with NAFLD from an Asian population, it was confirmed that lean NAFLD patients feature a milder metabolic profile compared to overweight and obese NAFLD patients, as estimated by indices including fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR) \[[@ref2]\]. Similar results were obtained from another study enrolling 187 Caucasian subjects, including healthy controls, lean and obese NAFLD patients; however, it was demonstrated that NAFLD patients did not differ regarding their impaired response to oral glucose challenge \[[@ref3]\]. Despite the fact that significantly fewer patients with lean NAFLD compared to obese NAFLD suffer from diabetes, it has been shown that patients with lean NAFLD and a medium waist circumference have greater odds for incident diabetes than patients with obese NAFLD and a medium waist circumference, as well \[[@ref4]\].

More recent data confirm that lean NAFLD is strongly and positively associated with the development of diabetes. Sung et al. demonstrated that lean NAFLD increases the risk of diabetes by 1.17 times (hazard ratio (HR) = 2.17, 95% CI: 1.56--3.03) in men and by 1.86 times in women (HR = 2.86, 95% CI: 1.50--5.46), while corresponding numbers further increase when fatty liver is assessed along with insulin resistance \[[@ref5]\]. Sinn *et al*. have also shown that lean NAFLD patients exhibit an 18% increase in the risk of incident diabetes compared to lean subjects without NAFLD (HR = 1.18, 95% CI: 1.03--1.35), suggesting the need for close monitoring of these patients for the potential development of metabolic abnormalities \[[@ref6]\].

Fasting plasma glucose appears to be a major indicator for the progression of NAFLD to non-alcoholic steatohepatitis (NASH) in patients with lean NAFLD \[[@ref7]\]. In addition, patients with lean NAFLD exhibit greater all-cause and cardiovascular mortality, compared to lean, non-NAFLD subjects, with diabetes arising as a crucial determinant for all-cause mortality (HR = 1.35, 95% CI: 1.04--1.75) \[[@ref8]\]. Vice versa, presence of diabetes at baseline appears to be an independent risk factor for the development of incident lean NAFLD \[[@ref9]\].

Collectively, it seems that even lean NAFLD patients are at high risk of glucose homeostasis derangement, which may in fact contribute to the progression of the underlying liver disease and the significant increase in related morbidity and mortality. In addition, diabetes represents an additional risk factor for all-cause and cardiovascular mortality for these patients. Thus, this sensitive sub-population warrants a close follow-up, including meticulous assessment of glucose homeostasis, even if the latter is normal at baseline.
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